Type I RAF inhibitors (GDC‐0879) and Type I1⁄2 ATP‐competitive RAF inhibitors (vemurafenib, dabrafenib, and encorafenib) are effective in BRAFV600E/K melanoma, while these agents instead promote RAS‐dependent dimerization and activation of wild‐type RAF proteins in RASmut melanoma [174, 175]. The gene discussed is RAF1; the disease is melanoma.